- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04192344
En studie for å vurdere sikkerheten, tolerabiliteten og farmakokinetikken til ABSK-021 hos pasienter med avansert solid svulst
En fase 1, åpen studie av ABSK021 for å vurdere sikkerhet, tolerabilitet og farmakokinetikk hos pasienter med avansert solid svulst
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The study will start with a dose escalation part of single-agent ABSK021 administered in repeated 28-day cycles in patients with advanced solid for safety and tolerability. The expansion part of oral ABSK021 at recommended dose of expansion (RDE) will be followed for further evaluating safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Siqing Fu, MD
- Telefonnummer: (713)792-4318
- E-post: siqingfu@mdanderson.org
Studer Kontakt Backup
- Navn: YUAN LU
- Telefonnummer: +86-21-68910052
- E-post: clinical@abbisko.cn
Studiesteder
-
-
California
-
Beverly Hills, California, Forente stater, 90212
- Aktiv, ikke rekrutterende
- Precision NextGen Oncology
-
-
Colorado
-
Denver, Colorado, Forente stater, 80218-1238
- Fullført
- SCRI at HealthOne
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Fullført
- The Winship Cancer Institute of Emory University
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Fullført
- MD Anderson Cancer Center
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina
- Rekruttering
- Beijing Jishuitan Hospital
-
Ta kontakt med:
- Xiaohui Niu, MD
-
Hovedetterforsker:
- Xiaohui Niu, MD
-
-
Guangzhou
-
Guangdong, Guangzhou, Kina
- Aktiv, ikke rekrutterende
- The First Affiliated Hospital of Sun Yat-sen University
-
-
Hebei
-
Shijiazhuang, Hebei, Kina
- Fullført
- Hebei Medical University Third Hospital
-
-
Henan
-
Zhengzhou, Henan, Kina
- Fullført
- The First Affiliated Hospital of Zhengzhou Universtity
-
Zhengzhou, Henan, Kina
- Aktiv, ikke rekrutterende
- Henan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina
- Aktiv, ikke rekrutterende
- Nanjing Drum Tower Hospital
-
Nanjing, Jiangsu, Kina
- Aktiv, ikke rekrutterende
- Jiangsu Province Hospital
-
-
Liaoning
-
Shenyang, Liaoning, Kina
- Fullført
- Liaoning Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina
- Fullført
- Huashan Hospital of Fudan University
-
Shanghai, Shanghai Municipality, Kina
- Fullført
- Shanghai Sixth People's Hospital
-
-
Shanxi
-
Xian, Shanxi, Kina
- Aktiv, ikke rekrutterende
- Xi'an Hong Hui Hospital
-
-
Sichuan
-
Chengdu, Sichuan, Kina
- Rekruttering
- West China Hospital of Sichuan University
-
Ta kontakt med:
- Yong Zhou, MD
-
Hovedetterforsker:
- Yong Zhou, MD
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina
- Rekruttering
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Ta kontakt med:
- Zhaoming Ye, MD
-
Hovedetterforsker:
- Zhaoming Ye, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically confirmed solid tumors that have progressed on or intolerant to standard therapy or whom no standard therapy exists
- ECOG (electrocorticogram) performance status 0~1
- Life expectancy ≥ 3 months
- Adequate organ function and bone marrow function
For patients with tenosynovial giant cell tumor (TGCT) :
- A diagnosis of TGCT [i ncluding pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT TS) (i) that has been histologically confirmed either by a pathologist at the treating institution or a central pathologist,and (ii) where surgical resection would be associated with potentially worsening functional limitation or severe morbidity (locally advanced disease), with morbidity determined consensually by qualified personnel (eg, two surgeons or a multi disciplinary tumor board);
- Measurable disease as defined by RECIST 1.1 (except that a minimal size of 2 cm is required), assessed from MRI scans;
- Others
For Adolescent Cohort (China only):
- Patient and/or legally acceptable representative should understand, sign, and date the written voluntary informed consent form prior to screening.
- Adolescents≥ 12 years of age and < 18 years at the time of informed consent.
- Body weight ≥ 40kg.
- A diagnosis of TGCT [including pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT-TS)] (i) that has been histologically confirmed either by local laboratory, and (ii) unresectable, defined as confirmed by assessment by at least two clinical experts (including at least one independent expert who is not part of the trial conduct), meeting one of the following 2 requirements: ①located in a complex anatomical site, is extensively invasive, and cannot be completely resected; ②surgical operation may cause dysfunction or serious complications.
- Measurable disease as defined by RECIST v1.1 (with at least 1 lesion ≥ 2 cm is required), assessed by MRI scans in local site prior to dosing.
- Others
Exclusion Criteria:
- Known allergy or hypersensitivity to any component of the investigational drug product Previous treatment with CSF-1(colony stimulating factor 1)/CSF-1R (colony stimulating factor 1 receptor) pathway inhibitors
- Known additional malignancy that is progressing or required active treatment within 3 years of the first dose of study treatment
- Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication
- Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment (chemotherapy with nitrosourea or mitomycin should be 6 weeks prior to initiation of study treatment)
- Major surgery within 4 weeks of the first dose of study drug and all surgical wounds must be healed and free of infection or dehiscence
- Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade ≤2 severity (CTCAE v5.0) with the exception of alopecia and vitiligo
- Prior corticosteroids as anti-cancer therapy within a minimum of 2 weeks of the first dose of study drug
- Concomitant use of strong inhibitors or inducers of CYP3A4
- Active central nervous system (CNS) metastases
- Impaired cardiac function or clinically significant cardiac disease
- Patients with Gilbert's Syndrome or other underlying conditions that may lead to a greater likelihood of developing LFT(liver function test) abnormalities during the study
- Known human immunodeficiency virus or active hepatitis B, or active hepatitis C infection
- Refractory/uncontrolled ascites or pleural effusion
- Pregnant or nursing
For patients with tenosynovial giant cell tumor (TGCT) :
- Known allergy or hypersensitivity to any component of the investigational drug product
- For expansion part, previous treatment with CSF 1/CSF 1R pathway inhibitors (not applicable for TGCT patients in US)
- Others
For Adolescent Cohort (China only):
- Known allergy or hypersensitivity to any component of the investigational drug product.
- Previous treatment with highly selective inhibitors targeting CSF-1/CSF-1R prior to first dosing. However, patients who have received prior treatment with multi-kinase inhibitors that include the CSF-1/CSF-1R pathway are allowed, such as Imatinib and Nilotinib.
- Know additional malignancy that required active treatment and may affect the patient's participation in the study or affect the outcome of the study as assessed by the Investigator. Exceptions include cured basal cell carcinoma of skin, squamous cell carcinoma of skin, and other carcinoma in situ.
- Others
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: ABSK021
Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by"3+3" escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles. |
ABSK021 oral capsule |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence and Severity of AEs
Tidsramme: Through study completion, an average of 6 months
|
Adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs) |
Through study completion, an average of 6 months
|
|
Incidence of DLTs
Tidsramme: At the end of Cycle 1 (each cycle is 28 days)
|
DLT(dose-limiting toxicity) |
At the end of Cycle 1 (each cycle is 28 days)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
PFS
Tidsramme: From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
Progression-Free Survival (PFS) |
From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
|
DoR
Tidsramme: From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
Duration of Response (DoR) |
From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
|
DCR
Tidsramme: 24 weeks post-dose
|
Disease Control Rate (DCR) |
24 weeks post-dose
|
|
Cmax
Tidsramme: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
The peak plasma concentration of a drug after administration |
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
|
tmax
Tidsramme: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
Time to reach Cmax |
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
|
Bioavailability
Tidsramme: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
The systemically available fraction of a drug |
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
|
Elimination half-life
Tidsramme: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
The time required for the concentration of the drug to reach half of its original value |
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Siqing Fu, MD, M.D. Anderson Cancer Center
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ABSK021-101
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .